GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Net Income Including Noncontrolling Interests

scPharmaceuticals (FRA:2SX) Net Income Including Noncontrolling Interests : €-53.36 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is scPharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

scPharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-12.98 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-53.36 Mil.

scPharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for scPharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals Net Income Including Noncontrolling Interests Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only -29.70 -26.48 -24.81 -34.78 -50.26

scPharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.47 -13.06 -14.65 -12.67 -12.98

scPharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-53.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

scPharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals (FRA:2SX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (FRA:2SX) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ENTA MCRB RENB AEON INZY IVVD GRTS DNTH CBUS PSTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SCPH:USA
Address
2400 District Avenue, Suite 310, Burlington, MA, USA, 01803
Website
https://www.scpharmaceuticals.com
scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals (FRA:2SX) Headlines

No Headlines